Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Individualized precision medicine].
Wullich B, Taubert H, Goebell PJ, Kuwert T, Beck M, Schott C, Baur AS, Eckstein M, Wach S. Wullich B, et al. Among authors: eckstein m. Urologie. 2023 Sep;62(9):879-888. doi: 10.1007/s00120-023-02151-z. Epub 2023 Aug 1. Urologie. 2023. PMID: 37526710 Review. German.
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N, Eckstein M, Kunath F, Heidegger I, Becker C, Rausch S; Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie. Klümper N, et al. Among authors: eckstein m. Urologie. 2023 Nov;62(11):1193-1199. doi: 10.1007/s00120-023-02175-5. Epub 2023 Sep 1. Urologie. 2023. PMID: 37658236 Review. German.
Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V, Eckstein M, Hartmann A, Stöhr R. Bahlinger V, et al. Among authors: eckstein m. Methods Mol Biol. 2023;2684:283-291. doi: 10.1007/978-1-0716-3291-8_17. Methods Mol Biol. 2023. PMID: 37410241
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V.. Breyer J, et al. Among authors: eckstein m. Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. Sci Rep. 2023. PMID: 37723173 Free PMC article.
Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach.
Henderson RH, French D, Stewart E, Smart D, Idica A, Redmond S, Eckstein M, Clark J, Sullivan R, Keeling P, Lawler M. Henderson RH, et al. Among authors: eckstein m. J Pharm Policy Pract. 2023 Jul 5;16(1):84. doi: 10.1186/s40545-023-00590-9. J Pharm Policy Pract. 2023. PMID: 37408046 Free PMC article.
Numerically Exact Simulation of Photodoped Mott Insulators.
Künzel F, Erpenbeck A, Werner D, Arrigoni E, Gull E, Cohen G, Eckstein M. Künzel F, et al. Among authors: eckstein m. Phys Rev Lett. 2024 Apr 26;132(17):176501. doi: 10.1103/PhysRevLett.132.176501. Phys Rev Lett. 2024. PMID: 38728727
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
Haas M, Kriegmair MC, Breyer J, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Zengerling F, Bolenz C, Burger M, Hartmann A, Eckstein M. Haas M, et al. Among authors: eckstein m. BJU Int. 2024 May 8. doi: 10.1111/bju.16389. Online ahead of print. BJU Int. 2024. PMID: 38717014
Bispecific T cell engager therapy for refractory rheumatoid arthritis.
Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C, Wirsching A, Wacker J, Wilhelm A, Auger JP, Pachowsky M, Eckstein M, Alivernini S, Zoli A, Krönke G, Uderhardt S, Bozec A, D'Agostino MA, Schett G, Grieshaber-Bouyer R. Bucci L, et al. Among authors: eckstein m. Nat Med. 2024 Apr 26. doi: 10.1038/s41591-024-02964-1. Online ahead of print. Nat Med. 2024. PMID: 38671240
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: eckstein m. J Clin Oncol. 2024 Apr 24:JCO2301983. doi: 10.1200/JCO.23.01983. Online ahead of print. J Clin Oncol. 2024. PMID: 38657187
716 results